Evofem Biosciences, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Evofem Biosciences, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2017 to Q2 2024.
  • Evofem Biosciences, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $2.75M.
  • Evofem Biosciences, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $71.6M, a 36% decline year-over-year.
  • Evofem Biosciences, Inc. annual Nonoperating Income (Expense) for 2023 was $70.8M, a 848% increase from 2022.
  • Evofem Biosciences, Inc. annual Nonoperating Income (Expense) for 2022 was $7.47M.
  • Evofem Biosciences, Inc. annual Nonoperating Income (Expense) for 2021 was -$38.4M, a 0.79% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $71.6M $2.75M +$3.97M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $67.7M -$1.97M -$3.19M -260% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $70.8M $1.27M -$2.46M -66% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 $73.3M $69.6M -$38.7M -35.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $112M -$1.22M +$100M +98.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $11.7M $1.23M +$4.18M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $7.47M $3.72M +$17.9M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 -$10.4M $108M +$139M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$149M -$102M -$109M -1414% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$40.1M -$2.96M -$1.68M -131% Jan 1, 2022 Mar 31, 2022 10-Q 2023-06-16
Q4 2021 -$38.4M -$14.1M -$9.39M -198% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-27
Q3 2021 -$29M -$30.7M -$27M -720% Jul 1, 2021 Sep 30, 2021 10-Q 2023-01-06
Q2 2021 -$2.04M $7.73M +$38M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$40.1M -$1.28M -$1.38M -1406% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$38.7M -$4.74M -$4.9M -3161% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$33.8M -$3.74M -$4.24M -850% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$29.5M -$30.3M -$6.79M -28.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$22.8M $98K +$4.53M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$27.3M $155K +$155K Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$27.4M $499K +$497K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$27.9M -$23.5M -$23.5M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$4.43M -$4.44M +$43.6M +90.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 -$48.1M $0 -$4.15M -100% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$43.9M $2K* -$65M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 $21M $0 -$154K -100% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 $21.2M -$48.1M -$48.4M -13718% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 $69.6M $4.15M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 $65M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 $154K Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 $353K Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.